NVG-291 in Spinal Cord Injury Subjects

Drug

Standing/walking/mobility

Online since 8 November 2024, updated 12 days ago

About this trial

This trial is enrolling 40 individuals with chronic (1-10 years) and subacute (10-49 days) cervical spinal cord injury to test the safety and effect of an experimental drug, NVG-291. If included, participants will receive a daily subcutaneous (under the skin) injection for 12 weeks of either: 1) NVG-291; or 2) a placebo drug. In lab studies, NVG-291 improved locomotion and bladder recovery. Final testing of central nervous system conduction (electrophysiology) as well as upper and lower limb function will be assessed after 16 weeks.

Included participants

Gender

All

Age

18 - 75 years

Injury level

C1 - C7

Severity (AIS)?

AIS-B

AIS-C

AIS-D

Time since injury

10 days - 10 years

Injury type

Traumatic

Healthy volunteers

C1-C7

Additionally, participants must

NOT have a spinal cord injury due to gunshot wound or penetrating injury

NOT have an implanted device in the brain or spinal cord

NOT have an implanted pacemaker

What’s involved

Type

Drug

Details

- participants will receive a single daily subcutaneous (under the skin) injection for 12 weeks of either 1) NVG-291 or 2) a placebo drug - Final testing of upper and lower limb function will be assessed after 16 weeks.

Potential benefits

Main benefits

Standing/walking/mobility

Additional benefits

Arm/hand function

General health

Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.

Wings for Life supports SCITrialsFinder

Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

Learn more

Back to results